NRXP Share Price Performance
US$3.03
0.93 (44.29%)
91.8% undervalued intrinsic discount
US$36.75
Fair Value
Price US$3.03
AnalystConsensusTarget US$36.75
AnalystHighTarget US$47.00
AnalystLowTarget US$25.00
Fair ValueUS$36.75
Share Pricen/a
NRx Pharmaceuticals, Inc. Stock Price
- 3 Narratives written by author
- 0 Comments on narratives written by author
- 28 Fair Values set on narratives written by author
NRXP Community Narratives
AN
Fair Value
·Fair Value US$36.75 91.8% undervalued intrinsic discount
Neuroplastic Treatments And Clinic Network Will Reshape Long Term Prospects For This Undervalued Biotech
0users have liked this narrative
0users have commented on this narrative
3users have followed this narrative
AN
Fair Value
·Fair Value US$47 93.6% undervalued intrinsic discount
Neuroplasticity-Based Treatments And Clinic Network Expansion Will Transform Long-Term Earnings Power
0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
AN
Fair Value
·Fair Value US$25 87.9% undervalued intrinsic discount
Complex Neuroplastic Treatments And Clinic Risks Will Challenge Progress Yet Ultimately Support Long-Term Promise
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
Neuroplastic Treatments And Clinic Network Will Reshape Long Term Prospects For This Undervalued Biotech
Catalysts About NRx Pharmaceuticals NRx Pharmaceuticals focuses on developing and commercializing treatments for severe mood and brain disorders, including depression, suicidality and PTSD, while building a network of interventional psychiatric clinics through its HOPE Therapeutics subsidiary. What are the underlying business or industry changes driving this perspective?Read more
AN
US$36.75
91.8% undervalued intrinsic discount
Fair Value
Profit Margin
49.63%
Future PE
3.29x
Price in 2029
US$44.96
Neuroplasticity-Based Treatments And Clinic Network Expansion Will Transform Long-Term Earnings Power
Catalysts About NRx Pharmaceuticals NRx Pharmaceuticals is a neuro-focused biopharmaceutical and services company developing treatments and delivery platforms for severe mood and brain disorders. What are the underlying business or industry changes driving this perspective?Read more
AN
US$47
93.6% undervalued intrinsic discount
Fair Value
Profit Margin
79.13%
Future PE
2.76x
Price in 2028
US$57.51
Complex Neuroplastic Treatments And Clinic Risks Will Challenge Progress Yet Ultimately Support Long-Term Promise
Catalysts About NRx Pharmaceuticals NRx Pharmaceuticals is a clinical stage biopharmaceutical company developing neuroplasticity driven drugs and integrated clinic based treatments for severe mood and brain disorders. What are the underlying business or industry changes driving this perspective?Read more
AN
US$25
87.9% undervalued intrinsic discount
Fair Value
Profit Margin
14.2%
Future PE
9.23x
Price in 2028
US$30.59
Trending Discussion
Recently Updated Narratives
AN
Neuroplastic Treatments And Clinic Network Will Reshape Long Term Prospects For This Undervalued Biotech
Fair Value: US$36.75 91.8% undervalued intrinsic discount
3 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
Neuroplasticity-Based Treatments And Clinic Network Expansion Will Transform Long-Term Earnings Power
Fair Value: US$47 93.6% undervalued intrinsic discount
1 fair value setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
Complex Neuroplastic Treatments And Clinic Risks Will Challenge Progress Yet Ultimately Support Long-Term Promise
Fair Value: US$25 87.9% undervalued intrinsic discount
0 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
Snowflake Analysis
NRx Pharmaceuticals, Inc. Key Details
Last Reported Earnings
Dec 31, 2025
Next Reporting Earnings
n/a
- -0.87
- 58.78%
- -2,336.49%
- 0%
About NRXP
- Founded
- 2015
- Employees
- 29
- CEO
- WebsiteView website
NRx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapeutics for the treatment of central nervous system disorders comprising suicidal depression, post-traumatic stress disorder (PTSD), and schizophrenia in the United States. It operates through NRx and Dura segments. The company develops NRX-101, an oral fixed-dose combination of D-cycloserine (DCS) and lurasidone in Phase 2/3 clinical testing for bipolar depression with sub-acute ideation and behavior; NRX-100, a preservative-free formulation of ketamine for intravenous infusion and for the treatment of suicidal depression; and KETAFREE, a generic preservative-free formulation of ketamine. It also provides precision-based interventional psychiatry services to patients with treatment-resistant depression and PTSD using a combination of neuroplastic drugs, transcranial magnetic stimulation (TMS), digital therapeutics, and hyperbaric therapy; ketamine infusion therapy; stellate ganglion blocks; Spravato administration; psychotherapy; and medication management. The company has a development and license agreement with Glytech LLC. NRx Pharmaceuticals, Inc. was founded in 2015 and is headquartered in Wilmington, Delaware.
